Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1107/week)
    • Manufacturing(535/week)
    • Technology(1109/week)
    • Energy(429/week)
    • Other Manufacturing(346/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Protalix BioTherapeutics

Jun 08, 2020
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
Jun 01, 2020
Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
May 28, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
May 22, 2020
Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020
May 11, 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Mar 18, 2020
Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
Mar 16, 2020
Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein
Mar 12, 2020
Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease
Mar 05, 2020
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020
Feb 10, 2020
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020
Feb 06, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
Feb 04, 2020
Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference
Jan 30, 2020
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020
Jan 01, 2020
Global fabry disease treatment market is expected to grow with a healthy CAGR over the forecast period from 2019-2025
Dec 19, 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Dec 09, 2019
Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
Nov 27, 2019
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease
Nov 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Nov 07, 2019
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
Oct 29, 2019
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019
  •  
  • Page 1
  • ››

Latest News

Sep 25, 2025

IonQ Achieves Record Breaking Quantum Performance Milestone of #AQ 64

Sep 25, 2025

EDB Contributions to PostgreSQL 18 Deliver Faster Performance, Stronger Security, and Greater Flexibility for...

Sep 25, 2025

Oklo Conducts Full-Scale Fuel-Assembly Flow Testing at Argonne National Laboratory

Sep 25, 2025

Accelsius Unveils Two-Phase Cooling Reference Design, Demonstrating Billions in Potential Energy Savings

Sep 25, 2025

T&S Brass Emphasizes End-User Safety as Faucet Recalls Highlight Compliance Gaps

Sep 25, 2025

CarMax Reports Second Quarter Fiscal Year 2026 Results

Sep 25, 2025

Clean Energy to Build Second Hydrogen Station for Foothill Transit’s Expanding Fleet of Low-emissions Buses

Sep 25, 2025

STEP Energy Services Ltd. Receives Non-Binding Offer From ARC Financial Corp.

View all News

Agenda

27
January
United States of AmericaThe Westin Arlington, Arlington, VA
Future Indirect Fires, January 27-28, 2026, The Westin Arlington, Arlington, VA
Future Indirect Fires, January 27-28, 2026, The Westin Arlington, Arlington, VA Supporting Next-Generation Capability...
03
December
United Kingdom Copthorne Tara Hotel, London, UK
Uncrewed & Autonomous Systems, 3 - 4 December 2025, Copthorne Tara Hotel, London, UK
Uncrewed & Autonomous Systems | 3 - 4 December 2025| Copthorne Tara Hotel, London, UK   Uncrewed & Autonomous...
28
October
Copthorne Tara Hotel, London, UK
Maritime ISR, 28-29 October 2025, Copthorne Tara Hotel, London, UK
Maritime ISR | 28-29 October 2025 | Copthorne Tara Hotel, London, UK   This year’s conference brings together senior...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia